APA (7th ed.) Citation

McCrimmon, R. J., Falla, E., Sha, J. Z., Alsaleh, A. J. O., Lew, E., Hudson, R., . . . Palmer, K. (2021). Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK. Diabetes Therapy, 12(12), 3217. https://doi.org/10.1007/s13300-021-01159-y

Chicago Style (17th ed.) Citation

McCrimmon, Rory J., Edel Falla, Jo Zhou Sha, Abdul Jabbar Omar Alsaleh, Elisheva Lew, Richard Hudson, Mike Baxter, and Karen Palmer. "Cost-Effectiveness of IGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK." Diabetes Therapy 12, no. 12 (2021): 3217. https://doi.org/10.1007/s13300-021-01159-y.

MLA (9th ed.) Citation

McCrimmon, Rory J., et al. "Cost-Effectiveness of IGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK." Diabetes Therapy, vol. 12, no. 12, 2021, p. 3217, https://doi.org/10.1007/s13300-021-01159-y.